Previous 10 | Next 10 |
2023-08-07 13:38:01 ET Royalty Pharma ( NASDAQ: RPRX ) is scheduled to announce Q2 earnings results on Tuesday, August 8th, before market open. The consensus EPS Estimate is $0.81 and the consensus Revenue Estimate is $536.59M. Over the last 3 months, EPS estimates hav...
2023-08-03 11:40:42 ET Summary On August 2, Blueprint Medicines, a pharmaceutical company developing medicines for treating cancer and blood diseases, released its financial results for the second quarter of 2023. Blueprint Medicines' revenue for the second quarter of 2023 was $57...
2023-07-26 09:37:00 ET When you invest in dividend stocks, you're normally doing so because you want a recurring payout. But in some cases, you can also set yourself up for some potential gains as well. This year, investors have been pivoting toward big artificial intelligence stocks and ha...
2023-07-19 15:41:47 ET Summary Shares of biopharmaceutical royalty concern Royalty Pharma plc have fallen 45% from their all-time high as inflation and a potential revenue decline from its number one asset weigh. Vertex Pharmaceuticals Incorporated, the maker of multi-blockbuster ...
NEW YORK, July 18, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2023 financial results on Tuesday, August 8, 2023 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a...
NEW YORK, July 17, 2023 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2023 of $0.20 per Class A ordinary share. The dividend will be paid on September 15, 2023, to shareholders of record at the...
2023-07-13 08:30:00 ET Summary June 2023 saw significant insider purchases in Lucid Group, Diversified Healthcare Trust, Akoya Biosciences, and Axon Enterprise. The Public Investment Fund bought $1.8 billion worth of shares in Lucid Group, increasing its ownership to 74.95%. Diver...
2023-06-10 18:55:00 ET The Citi quantitative team is still confident about its Oversold Strategy, despite a second stumble in returns this year. "Our systematic Oversold Strategy posted its second loss (-4%) this year in May, as the equity market is following more closely on the credit ...
2023-06-10 11:35:00 ET Summary Royalty Pharma acquires royalties on drugs in the commercial phase and the development phase. Thanks to a milestone payment, this year's cash receipts will come in close to $3B. The annualized free cash flow result for the next few years will lik...
NEW YORK, June 07, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to present at the Goldman Sachs 44 th Annual Global Healthcare Conference on June 13, 2023 at 5:00 p.m. ET / 2:00 p.m. PT. The webcast will be accessible from Royalty Pharm...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, July 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2024 financial results on Thursday, August 8, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 ...
NEW YORK, July 17, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2024 of $0.21 per Class A ordinary share. The dividend will be paid on September 13, 2024, to shareholders of record at the...